Click for best price
NonAlcoholic Steatohepatitis NASH Treatment Market Size, Share 2022
This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Treatment in Global, including the following market information:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Alcoholic Steatohepatitis (NASH) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Off-Label Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis (NASH) Treatment include Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc. and Zydus Cadila, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Type, 2021 (%)
Off-Label
Therapeutic
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
| Report Attributes |
Report Details |
| Report Title |
Non-Alcoholic Steatohepatitis (NASH) Treatment Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size: 2021 VS 2028
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Treatment Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Markets, 2021 & 2028
4.1.2 Off-Label
4.1.3 Therapeutic
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2022
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2023-2028
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2022
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2023-2028
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2021 & 2028
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2022
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2023-2028
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Allergan Plc (Tobira)
7.1.1 Allergan Plc (Tobira) Corporate Summary
7.1.2 Allergan Plc (Tobira) Business Overview
7.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.1.4 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.1.5 Allergan Plc (Tobira) Key News
7.2 Bristol Myers Squibb
7.2.1 Bristol Myers Squibb Corporate Summary
7.2.2 Bristol Myers Squibb Business Overview
7.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.2.4 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.2.5 Bristol Myers Squibb Key News
7.3 Galmed Pharmaceuticals
7.3.1 Galmed Pharmaceuticals Corporate Summary
7.3.2 Galmed Pharmaceuticals Business Overview
7.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.3.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.3.5 Galmed Pharmaceuticals Key News
7.4 Genfit SA
7.4.1 Genfit SA Corporate Summary
7.4.2 Genfit SA Business Overview
7.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.4.4 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.4.5 Genfit SA Key News
7.5 Gilead Sciences, Inc.
7.5.1 Gilead Sciences, Inc. Corporate Summary
7.5.2 Gilead Sciences, Inc. Business Overview
7.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.5.4 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.5.5 Gilead Sciences, Inc. Key News
7.6 Intercept Pharmaceuticals, Inc.
7.6.1 Intercept Pharmaceuticals, Inc. Corporate Summary
7.6.2 Intercept Pharmaceuticals, Inc. Business Overview
7.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.6.4 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.6.5 Intercept Pharmaceuticals, Inc. Key News
7.7 Zydus Cadila
7.7.1 Zydus Cadila Corporate Summary
7.7.2 Zydus Cadila Business Overview
7.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.7.4 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2017-2022)
7.7.5 Zydus Cadila Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Treatment Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Allergan Plc (Tobira) Corporate Summary
Table 31. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 32. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Bristol Myers Squibb Corporate Summary
Table 34. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 35. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Galmed Pharmaceuticals Corporate Summary
Table 37. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 38. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Genfit SA Corporate Summary
Table 40. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 41. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Gilead Sciences, Inc. Corporate Summary
Table 43. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 44. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Intercept Pharmaceuticals, Inc. Corporate Summary
Table 46. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 47. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Zydus Cadila Corporate Summary
Table 49. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 50. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Treatment Segment by Type in 2021
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Treatment Segment by Application in 2021
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2021
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 12. US Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 24. China Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
